Clinical Trials Browser

Phase 1/2 × camrelizumab × Genitourinary × Clear all

NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms